Bringing the Oncology Community Together

Dr. Mateos on Elderly Patients With Newly Diagnosed MM

María-Victoria Mateos
Published Online: Monday, December 16, 2013
María-Victoria Mateos, MD, PhD, associate professor, hematology, University Hospital of Salamanca, Salamanca, Spain, discusses the design and results of a phase II trial that she presented at the 2013 American Society of Hematology (ASH) Meeting.

In the GEM2010MAS65 trial, researchers conducted a comparison of sequential and alternating administration of bortezomib, melphalan, and prednisone and lenalidomide plus dexamethasone in elderly patients with newly diagnosed multiple myeloma.

The combination of melphalan, bortezomib, lenalidomide, and steroids in this patient population in a sequential or alternating scheme is feasible, Mateos says. In terms of complete remission, the alternating scheme showed superior efficacy, though a longer follow-up is needed.

Related Articles
FDA Approves First-Line Ofatumumab for Fludarabine-Ineligble Patients With CLL
The FDA has approved ofatumumab plus chlorambucil for previously untreated patients with chronic lymphocytic leukemia who are considered inappropriate for treatment with fludarabine therapy.
Defining and Predicting Response to HMAs in MDS
In this segment, panelists discuss the lack of a clear connection between response to hypomethylating agents and molecular genetics as well as the larger role for cytogenetic assessment of response for patients with myelodysplastic syndrome.
Hypomethylating Agents in the Treatment of High-Risk MDS
In this section, panelists discuss the intricacies of administering hypomethylating agents for the treatment of patients with high-risk myelodysplastic syndrome.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.